News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Investidor10 Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Neuronetics, Inc. (NASDAQ:STIM) recently reported quarterly results showing better-than-expected revenues of US$42m and smaller statutory losses of US$0.05 per share. Analysts have largely maintained revenue forecasts for 2026 at US$161.8m but significantly reduced loss per share estimates to US$0.35. The average price target has …
This article reports on Neuronetics Inc.'s Form 8K filing for August 11, without providing further details on the content of the filing. It is a brief announcement from Investing.com, typical of financial news outlets reporting SEC filings. The piece primarily serves as a placeholder …
Neuronetics Inc. reported increased revenues for Q2 and H1 2026, primarily driven by its Greenbrook segment, and narrowed its net loss. However, the company flagged substantial doubt about its ability to continue as a going concern due to a projected failure to meet a …
Earnings Call Insights: Neuronetics (STIM) Q2 2026 MANAGEMENT VIEW * "I'm pleased to report the second quarter began to reflect our steady execution against the goals I cited last quarter. Total revenue was $41.6 million, up approximately 9% versus the second quarter of last …
Key Points Interested in Neuronetics, Inc.? Here are five stocks we like better. Q2 results improved significantly: Revenue rose 9.1% year over year to $41.6 million, while the net loss narrowed to $3.4 million and adjusted EBITDA turned positive at $0.3 million. Greenbrook was …
Neuronetics has released an investor presentation detailing its NeuroStar TMS and Greenbrook clinic network strategy. The company provided FY 2026 revenue guidance of $160 million to $164 million, projecting 7% to 10% year-on-year growth, alongside a gross margin outlook of 48% to 50%. It …
Neuronetics (STIM) has received a "Buy" rating and a $5 target price from BTIG, signaling bullish sentiment due to its expanding depression-treatment technology adoption and vertically integrated psychiatry platform. The company's acquisition of 93 Greenbrook-operated treatment centers and the establishment of a National Center …
Neuronetics (NASDAQ:STIM) reported strong second-quarter results, surpassing analyst expectations with an adjusted loss per share of -$0.05 and revenue of $41.6 million. The company's stock surged over 15% in pre-market trading, driven by a 9.1% year-over-year revenue increase, primarily from its Greenbrook clinic segment. …
Neuronetics, Inc. reported a 9.1% increase in total revenue to $41.6 million for Q2 2026, driven by a 16.8% rise in Greenbrook healthcare clinic revenue. The company also significantly improved its adjusted EBITDA to $0.3 million and reduced its net loss to $3.4 million. …
Neuronetics Inc is projected to report a loss of 12 cents per share, according to an earnings preview. The article, sourced from Reuters, provides this financial expectation. Readers can access the full article through TradingView.
Neuronetics is scheduled to release its financial results pre-market on August 11. Analysts are anticipating an earnings per share (EPS) of -$0.12, with revenue projected to be around $15.54 million. Investors will be closely watching these figures for insights into the company's performance.
Jorey Chernett, a major shareholder in Neuronetics, Inc. (STIM), has increased his beneficial ownership to 15.22% with 10,588,988 shares. He has acquired these shares using personal funds totaling approximately $20.68 million. Chernett and Neuronetics have reached an agreement granting him the opportunity to recommend …
Neuronetics has reached an agreement with its second-largest shareholder, Jorey Chernett, regarding board representation. Chernett, an activist shareholder, will recommend a new director and has expressed support for the company's management following discussions on its financial health and capital optimization. This development comes as …
Neuronetics (NASDAQ: STIM) has granted equity inducement awards in the form of restricted stock units (RSUs) to five new non-executive employees. These awards, made under the company's 2020 Inducement Incentive Plan and in accordance with Nasdaq Listing Rule 5635(c)(4), vest over three to four …
Neuronetics, Inc. announced an inducement grant of restricted stock units (RSUs) to its new Chief Financial Officer, Matthew Bennett. This grant, totaling 167,490 RSUs, was made outside of the company's existing equity compensation plans but was approved by the Compensation Committee in accordance with …
Neuronetics Inc (STIM) exhibits an institutional shareholding score of 5.00, placing it 107th within the Healthcare Equipment & Supplies industry. The company's institutional shareholding proportion recently increased by 11.24% quarter-over-quarter to 68.80%. The largest institutional shareholder is Bill Nygren | OAKMX, holding 5.49K shares.
This article provides a risk assessment for Neuronetics Inc (STIM), detailing its performance against the Healthcare Equipment & Supplies industry. It highlights the company's risk score of 2.08, ranking 160 out of 199 in its industry, and its beta of 1.07 suggesting higher volatility …
This article analyzes the financial health of Neuronetics Inc (STIM), indicating a weak financial status with a score of 6.57 out of 10, ranking 149th in its industry. Despite this, the company showed a 7.75% year-over-year revenue increase and a 14.87% net profit increase …
Neuronetics (NASDAQ: STIM) announced the grand opening of Greenbrook Mental Wellness Centers' National Center of Excellence in Rockville, Maryland. This new 7,000-square-foot facility, overseen by Neuronetics' CEO Geoffrey Grammer, aims to be a blueprint for advanced, patient-centered mental health care. The center focuses on …
Neuronetics has announced the grand opening of its Greenbrook Mental Wellness Centers' National Center of Excellence in Rockville, Maryland. This 7,000-square-foot facility, overseen by Chief Medical Officer Dr. Geoffrey Grammer, will expand access to advanced treatments like NeuroStar TMS and SPRAVATO for complex psychiatric …
Neuronetics, Inc. will release its second quarter 2026 financial and operational results before market open on August 11, 2026, followed by a conference call at 8:30 a.m. Eastern Time. The company, known for its NeuroStar® TMS technology and extensive network of interventional psychiatry clinics, …
Neuronetics (NASDAQ: STIM) announced it will release its second quarter 2026 financial and operating results before market open on Tuesday, August 11, 2026. The company will also host a conference call on the same day at 8:30 a.m. Eastern Time to discuss the results, …
Neuronetics (NASDAQ: STIM) has opened Greenbrook Mental Wellness Centers’ National Center of Excellence in Rockville, Maryland. This nearly 7,000-square-foot facility will serve as a national blueprint for advanced interventional psychiatry, offering high-volume NeuroStar TMS and SPRAVATO operations. The center will also act as Greenbrook’s …
Greenbrook Mental Wellness Centers, a subsidiary of Neuronetics, Inc., has opened its largest facility to date in Rockville, Maryland. This 7,000-square-foot "National Center of Excellence" will serve as a model for advanced mental health care, focusing on treatment-resistant depression using NeuroStar Advanced Therapy and …
This article details the shareholder structure of Neuronetics Inc (STIM), listing its major shareholders, their proportion of holdings, and the types of shareholders (e.g., private equity, individual investors, hedge funds). It also provides institutional shareholding data over several quarters and shows recent shareholder activity, …
Search by ticker symbol or company name and select a result to open its chart.